Covid-19: the Medicines Safety Agency withdraws a nasal spray from the market

“The technical documents of the product do not present sufficient clinical evidence to justify use against the SARS-CoV-2 virus”, indicates the ANSM.

The virucidal nasal spray Previdspray, presented as a protector against Covid-19; can no longer be marketed in France, announced this Friday the National Agency for the Safety of Medicines (ANSM).

The product, manufactured by a company registered in Belgium, did not meet the requirements of the health authorities.

“According to the Belgian Federal Agency for Medicines and Health Products, the product’s technical documents do not present sufficient clinical evidence to justify use against the SARS-CoV-2 virus responsible for Covid-19 disease”, perhaps we read in a press release on the ANSM website.

“As a result, the marketing of this product in pharmacies or any other place in France is stopped”, warns the National Medicines Safety Agency.

Not the first spray

Already, in February 2021, the ANSM had withdrawn a product marketed by a Bouches-du-Rhône company under the names “Cov-Defense nasal spray” or “Biokami nasal spray”, a few days before it was widely broadcast, relieves our colleagues of West France.

The manufacturer assured that its spray based on ionized water neutralized 99% of the viral load. He had been asked to substantiate these allegations. “We have not received any clinical validation data demonstrating the performance and safety of use”, noted the ANSM.

Leave a Comment